业绩稳增，发展进入高质量新周期 主要观点： ⚫[Table_Summary] 事件： | --- | |-------------------------------------------------------------| | 8 月 27 日公司发布 2024 年中期业绩报告，24H1 公司实现营业总 | | 收入 42.52 亿元（+9.02%），实现归母净利润 12.41 亿元 | | （+0.15%），实现扣非归母净利润 11.29 亿（-6.03%）；毛利率 | | 40.88%，净利率 29.19%。 | ⚫ 点评： ✓ 符合预期，经营稳中向上，一次性费用影响利润 | --- | |--------------------------------------------------------------| | 24Q2 公司实现营收 21.96 亿元（+19.51%），实现归母净利润 | | 亿元（-7%），实现扣非归母净利润 5.3 亿元（+9.22%）。24H1 | | 司主要的非经营性损益包含：1）一次性政府补助 3333 万元； | | 持有金融资产等产生的公允价值变动损益以及处置 ...

证券代码：002252 证券简称：上海莱士 上海莱士血液制品股份有限公司 投资者关系活动记录表 编号：2024-006 | --- | --- | --- | |------------------------|-------------------|---------------------------------| | | √ 特定对象调研 | □ 分析师会议 | | 投资者关系活动类别 | □ 媒体采访 | 业绩说明会 | | | □ 新闻发布会 | 路演活动 | | | □ 现场参观 | □其他（请文字说明其他活动内容） | | | 国君资管 | | | | 嘉实基金 | | | | 长江证券 | | | | 中邮证券 | | | | 富国基金 | 林庆 | | | 申万宏源 | | | | 华安证券 | | | | 招商基金 | | | 参与单位名称及人员姓名 | 永赢基金 西南证券 | 杜向阳 | | | 安信基金 | | | | 太平基金 | | | | 国联安基金 | | | | 易方达基金 | | | | 财通证券资管 | | | | 汇添富基金 | | | | 百年保险资管 | | | 时 ...

Investment Rating - The report maintains a "Recommended" rating for Shanghai Laishi, with a projected market capitalization of 625 billion yuan based on the recent transaction of selling 20% of its shares for 125 billion yuan [2]. Core Views - The company reported a revenue of 4.252 billion yuan for the first half of 2024, a year-on-year increase of 9.02%, while the net profit attributable to shareholders was 1.241 billion yuan, a slight increase of 0.15%. The investment net income saw a significant rise of 69% to 340 million yuan [1][2]. - The revenue growth in Q2 2024 was driven by strong sales of albumin and factor products, despite a decline in the sales of immunoglobulin [1]. - The gross margin slightly decreased due to an increase in the proportion of low-margin products and currency fluctuations, with a gross margin of 41% for H1 2024, down 2 percentage points year-on-year [1]. Financial Performance Summary - For H1 2024, the revenue from imported albumin was 1.955 billion yuan, up 18.87%, accounting for 46% of total revenue, with a gross margin of 17.86%, down 2 percentage points [1]. - The revenue from self-produced albumin was 800 million yuan, up 17.21%, with a gross margin of 46.21%, an increase of 2 percentage points [1]. - The revenue from immunoglobulin decreased by 15.50% to 839 million yuan, while the revenue from other blood products increased by 15.69% to 607 million yuan [1]. - The management expense ratio increased in the short term, while the sales and R&D expense ratios remained stable [1]. - The company forecasts revenues of 8.640 billion yuan, 9.587 billion yuan, and 10.627 billion yuan for 2024, 2025, and 2026 respectively, with net profits projected at 2.198 billion yuan, 2.527 billion yuan, and 2.914 billion yuan for the same years [3].

2024/6/30 | 期 | 末 | 数 | 期 | 初 | 数 | 期 | 末 | 数 | 期 | 初 | 数 | 项 | 项 | 目 | 目 | 合 | 并 | 母 | 公司 | 合 | 并 | 母 | 公司 | 合 | 并 | 母 | 公司 | 合 | 并 | 母 | 公司 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

关于 2024 年中期利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）于 2024 年 8 月 26 日召开第六届 董事会第三次会议及第六届监事会第二次会议，审议通过了《2024 年中期利润 分配方案》等，根据《公司法》、中国证监会《上市公司监管指引第 3 号—上市 公司现金分红》、深圳证券交易所《上市公司自律监管指引第 1 号—主板上市公 司规范运作》等相关法律、法规、规范性文件及《公司章程》的规定，为进一步 提高分红频次，增强投资者回报水平，结合公司实际情况，制定 2024 年中期利 润分配方案如下： 证券代码：002252 证券简称：上海莱士 公告编号：2024-061 上海莱士血液制品股份有限公司 公司拟定的2024年半年度利润分配方案为：拟以分红派息股权登记日总股本 （扣除公司回购专用证券账户持有公司股票）为基数，向全体股东每10股派发现 金股利0.37元人民币（含税）。若公司以6,635,984,837股（目前总股本6,637,984,837 股扣除回购专用证券账户持有的股票2,000,0 ...

证券代码：002252 证券简称：上海莱士 公告编号：2024-058 上海莱士血液制品股份有限公司 1、审议通过了《2024 年半年度报告全文及摘要》 经审核，监事会认为：董事会编制和审核公司2024年半年度报告全文及摘要 的程序符合法律、行政法规和中国证券监督管理委员会的相关规定，报告内容真 实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 表决结果：3 票同意，0 票弃权，0 票反对。 《2024 年半年度报告》全文刊登于巨潮资讯网（www.cninfo.com.cn），《2024 年半年度报告摘要》同时刊登于《证券时报》、《中国证券报》、《上海证券报》、 《证券日报》和巨潮资讯网（www.cninfo.com.cn），供投资者查阅。 2、审议通过了《2024年半年度募集资金存放与使用情况的专项报告》 表决结果：3 票同意，0 票弃权，0 票反对。 1 关于第六届监事会第二次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第六届监事会第二次会议于 2024 年 ...

关于第六届董事会第三次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第六届董事会第三次会议于 2024 年 8 月 16 日以电话和邮件方式发出会议通知，并于 2024 年 8 月 26 日上午 9 点 以通讯方式召开。 本次会议应出席董事 9 名，实际出席董事 9 名。本次会议由公司董事长谭丽 霞女士召集和主持。会议的召集、召开与表决程序符合《公司法》和《公司章程》 等有关规定。会议在保证所有董事充分发表意见的前提下，全体与会董事经投票 表决，一致作出如下决议： 证券代码：002252 证券简称：上海莱士 公告编号：2024-057 上海莱士血液制品股份有限公司 根据公司 2024 年半年度财务报告（未经审计），公司 2024 年半年度实现净 1 利润为 777,832,264.27 元（母公司报表），2024 年半年度合并报表中归属于上市 公司股东的净利润为 1,240,798,423.17 元，截至 2024 年 6 月 30 日，公司实际可 供股东分配的利润为 4,393,749,578.33 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 4,252,338,864.23, representing a 9.02% increase compared to CNY 3,900,625,795.05 in the same period last year[10]. - The net profit attributable to shareholders for the first half of 2024 was CNY 1,240,798,423.17, a slight increase of 0.15% from CNY 1,238,999,444.63 in the previous year[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 6.03%, amounting to CNY 1,128,729,566.55 compared to CNY 1,201,167,722.56 in the same period last year[10]. - The basic earnings per share for the first half of 2024 was CNY 0.187, reflecting a 1.63% increase from CNY 0.184 in the same period last year[10]. - The total assets at the end of the reporting period were CNY 32,372,700,012.22, which is a 1.39% increase from CNY 31,928,453,993.18 at the end of the previous year[10]. - The net assets attributable to shareholders increased by 3.75%, reaching CNY 30,746,632,018.70 compared to CNY 29,633,949,195.13 at the end of the previous year[10]. - The weighted average return on net assets was 4.10%, a decrease of 0.07 percentage points from 4.17% in the previous year[10]. - The total operating revenue for the first half of 2024 reached CNY 4,252,338,864.23, an increase of 9.0% compared to CNY 3,900,625,795.05 in the same period of 2023[177]. - Total operating costs amounted to CNY 3,044,769,048.29, up 13.1% from CNY 2,691,638,281.71 year-on-year[177]. - Operating profit for the first half of 2024 was CNY 1,548,819,448.69, reflecting a slight increase from CNY 1,458,463,554.09 in the previous year[177]. Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -47,549,432.62, a significant decline of 103.32% from CNY 1,433,444,222.02 in the previous year[10]. - The company reported a cash and cash equivalents balance of 1,891,837,596.46 RMB at the end of the first half of 2024, down from 3,542,092,429.90 RMB a year earlier[183]. - Cash inflow from operating activities totaled 1,176,910,017.45 RMB, slightly up from 1,078,045,270.62 RMB in the previous year[184]. - Total cash outflow from operating activities was 772,524,350.45 RMB, compared to 674,774,901.94 RMB in the same period of 2023[184]. - The company reported a significant increase in export revenue, which rose by 351.55% to ¥30,127,465.80, indicating successful international market expansion[32]. - The company reported a total of CNY 348,617.97 in other income, which adds to the overall revenue stream[195]. Research and Development - Research and development expenses rose by 22.05% to ¥106,025,740.46, reflecting the company's increased investment in R&D projects[31]. - The company is committed to ongoing research and development in blood product technologies to enhance its product offerings[14]. - The company has allocated 100 million RMB for R&D in new technologies related to blood product safety and efficacy[71]. - The company successfully obtained clinical approval for its first global monoclonal antibody treatment for hemophilia, SR604 injection, which is currently in the patient enrollment phase[26]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[177]. Market Expansion and Strategy - The company plans to expand its market presence through exclusive distribution agreements for blood products in mainland China[14]. - The company is focusing on building a compliant, professional, and precise marketing system to enhance operational efficiency and ensure regulatory compliance[27]. - The company aims to leverage big data and AI technologies for precise marketing and customer service improvements[27]. - The company is actively pursuing technological upgrades, including a project to enhance the GMP standards for blood products, which is projected to increase production capacity by 100,000 bottles annually[81]. - The company is exploring potential acquisitions of smaller biotech firms to enhance its product portfolio and market reach[70]. Shareholder and Governance - The company announced a cash dividend of CNY 0.37 per 10 shares (including tax) to all shareholders[2]. - The company declared a cash dividend of 0.37 CNY per share, totaling 245,531,438.97 CNY, which represents 100% of the distributable profit[60]. - The total number of shares for the cash dividend distribution is based on 6,635,984,837 shares, excluding shares held in the company's repurchase account[60]. - The company has implemented an employee stock ownership plan, with 30,990,000 shares allocated to 262 participants, representing 0.47% of the total shares[61]. - The company completed the election of the sixth board of directors on July 29, 2024, with a total of 9 directors, of which Haier Group controls the majority[151]. Risks and Challenges - The company faces potential risks including raw material supply risks and rising plasma costs, which may impact future operations[2]. - The company faces risks related to the supply of raw plasma, which remains tight due to regulatory constraints, impacting production capacity[55]. - The company reported a significant increase in costs due to rising wages and inflation, which poses a risk to plasma collection operations[56]. - The company is exposed to foreign exchange risks due to its import trade primarily settled in USD, and it is taking steps to monitor and manage these risks[56]. Environmental Compliance - The company has established a comprehensive waste management strategy, including the use of third-party disposal services for medical and hazardous waste[86]. - The wastewater treatment station has a capacity of 250m³/d, achieving an average COD discharge concentration reduction of over 98.1%[87]. - The company has implemented noise reduction measures, including sound insulation for boiler rooms and generator rooms[91]. - The company has established an emergency response plan for environmental incidents, with the latest revision filed in September 2023[93]. - The company has not reported any exceedance of pollutant discharge limits across various categories, including sulfur dioxide and volatile organic compounds[85]. Acquisitions and Partnerships - GDS acquired the rights and obligations related to the Single Molecule Counting (SMC) technology for $202 million, which is approximately RMB 1.43 billion[11]. - The company has established a strategic partnership with Klibor, which will enhance its market competitiveness and profitability through exclusive distribution agreements for human albumin products in China[28]. - The company is involved in a strategic cooperation agreement with Grifols, focusing on production quality, technology research, and sales channels[142]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and expand its service offerings[200]. Corporate Structure and Changes - The company underwent a change in controlling shareholder to Haiyingkang (Qingdao) Medical Technology Co., Ltd. on July 30, 2024, with Haier Group becoming the actual controller[129]. - The company has not experienced any changes in its board of directors or senior management during the reporting period[59]. - The report indicates that the company is focusing on expanding its market presence and enhancing its product offerings through strategic partnerships[161].

上海莱士血液制品股份有限公司 监事会关于第六届监事会第二次会议相关事项的书面审核 意见 一、监事会对2024年半年度报告的书面审核意见 公司第六届监事会第二次会议对《上海莱士血液制品股份有限公司2024年半 年度报告全文及摘要》进行认真审核。经审核，监事会认为： 董事会编制和审核公司2024年半年度报告全文及摘要的程序符合法律、行政 法规和中国证券监督管理委员会的相关规定，报告内容真实、准确、完整地反映 了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 二、监事会对2024年中期利润分配方案的书面审核意见 公司第六届监事会第二次会议就《2024 年中期利润分配方案》进行了认真 审核，认为： 根据公司 2024 年半年度财务报告（未经审计），公司 2024 年半年度实现净 利润为 777,832,264.27 元（母公司报表），2024 年半年度合并报表中归属于上市 公司股东的净利润为 1,240,798,423.17 元，截至 2024 年 6 月 30 日，公司实际可 供股东分配的利润为 4,393,749,578.33 元（母公司报表），合并报表实际可供股东 分配的利润为 9,360,6 ...

证券代码：002252 证券简称：上海莱士 公告编号：2024-056 上海莱士血液制品股份有限公司 关于剩余回购股份注销完成暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次注销存放于公司回购专用证券账户中的股份 7,495,921 股，占回购股 份注销前公司总股本的 0.1128%，本次注销完成后，公司总股本由 6,645,480,758 股减少至 6,637,984,837 股。 2、经中国证券登记结算有限责任公司深圳分公司确认，公司本次回购股份 注销事宜已于 2024 年 8 月 16 日办理完成。 上海莱士血液制品股份有限公司（"公司"）因注销剩余回购股份导致公司总 股本产生变化，根据《公司法》、《上市公司股份回购规则》、《深圳证券交易所上 市公司自律监管指引第 9 号——回购股份》等有关法律法规、部门规章、规范性 文件的有关规定，现将本次剩余回购股份注销完成暨股份变动情况公告如下： 一、剩余回购股份情况 公司于 2023 年 6 月 2 日召开了第五届董事会第二十四次（临时）会议，审 议通过了《关于回购公司股份方案 ...